Specific monoclonal antibody-based immunotherapy by targeting the RCC-associated antigen carbonic anhydrase-IX(G250/MN)

Urologe A. 2004 Sep:43 Suppl 3:S146-7. doi: 10.1007/s00120-004-0609-3.
No abstract available

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Antibody Specificity / immunology*
  • Antigens, Neoplasm / immunology*
  • Carbonic Anhydrase IX
  • Carbonic Anhydrases / immunology*
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / immunology
  • Clinical Trials as Topic
  • Cytotoxicity Tests, Immunologic
  • Dose-Response Relationship, Drug
  • Drug Delivery Systems*
  • Drug Therapy, Combination
  • Humans
  • Interleukin-2 / adverse effects
  • Interleukin-2 / therapeutic use
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / immunology
  • Neoplasm Metastasis
  • Rituximab
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, Neoplasm
  • G250 monoclonal antibody
  • Interleukin-2
  • Rituximab
  • CA9 protein, human
  • Carbonic Anhydrase IX
  • Carbonic Anhydrases
  • Trastuzumab